
Hemolens Diagnostics sp. z o.o.
Manufacture of medical and dental instruments and supplies
Overview
Hemolens Diagnostics develops non-invasive cardiac diagnostic software, including Cardiolens Viewer®, a cloud-based AI tool that transforms coronary CT angiography (CCTA) into a patient-specific 3D visualization and supports the identification of stenoses. Its FFR-CT Pro® technology enables detailed anatomical and functional evaluation of coronary arteries; its diagnostic methods use computational fluid mechanics.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 |
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 91 days late). 3 of 6 audited by a statutory auditor.
- 202508/07/2026
- 202408/07/2025
- 202312/07/2024
- 202206/07/2023
- 202114/10/2022
- 202023/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Cardiolens Viewer® with MDR certification – official handover by TÜV Rheinland
The official handover of the MDR certificate by the notified body TÜV Rheinland is an important milestone for us – confirming several years of work, many key design decisions, and the commitment of the entire Hemolens Diagnostics team. From certification to official handover In May 2026, we successfully completed the conformity assessment of Cardiolens Viewer® […]

How can technology give us more time? Hemolens Diagnostics at IT UNPLUGGED conference
Can technology give us more time? In healthcare, the answer is yes. More time for prevention, faster diagnosis, and more effective treatment. This idea was at the core of our participation in the IT UNPLUGGED conference in Lublin. IT UNPLUGGED – a meeting place for technology and business The IT UNPLUGGED event, organized by the […]

MDR Certified: Cardiolens Viewer® Clears a Rigorous EU Regulatory Threshold
We have successfully completed the MDR (EU) 2017/745 conformity assessment procedure for Cardiolens Viewer®. The assessment was conducted by TÜV Rheinland LGA Products GmbH, a notified body registered with the European Commission under number 0197. CE marking paves the way for the commercialization of our system in the European market. What MDR certification means in […]

Shaping the Future of Interventional Cardiology at EAPCI Summit 2026
On 19–20 February 2026, we participated in the EAPCI Summit 2026 held in Munich, Germany. This year’s edition was guided by the theme ‘Bringing together scientific rigour, multidisciplinary expertise, and training for the next generation.’ The two-day programme created a platform for in-depth discussions on access to care, the implementation of clinical standards, and the […]

The topic of AI and innovation dominated the 4th Conference of the Polish Cardiac Society (Wroclaw Department)
On February 20-21, 2026, the 4th Conference of the Polish Cardiac Society (Wroclaw Department) took place in Wrocław. The event gathered local physicians and leaders in cardiology and cardiac surgery, as well as specialists interested in the diagnosis and treatment of cardiovascular diseases. The two-day conference provided a platform for exchanging experiences and presenting the […]

Arm in arm: how in silico modelling and AI tackle the “grey zone” in coronary diagnostics
During the latest Avicenna Alliance webinar, our team presented how combining CCTA, in silico patient‑specific modelling, and AI may help address one of the most discussed areas in coronary diagnostics – the functional “grey zone” between clearly significant and clearly non‑significant lesions. In the presentation, CSO Ziemowit Ostrowski and co‑founder Andrzej Kosior described an approach […]
Industry
Offer
- CT angiography analysis software
- Three-dimensional coronary artery visualization
- Blood vessel segmentation
- FFR-CT diagnostics
- Blood flow modelling
Websites
The site is available in: Polish and English.
- hemolens.comNon-invasive cardiac diagnostics – HemolensWordPress 7.1ElementorHubSpotGoogle AnalyticsGoogle Tag ManagerYoast SEOWWPMLLLiteSpeed
Trademarks
The company holds 5 active trademarks registered with the Polish Patent Office. The first mark was filed in 2021.
| Mark | Protected until | |
|---|---|---|
| Cardiolens (word) | Apr 26, 2032 | |
| HEMOLENS (word) | Jan 21, 2032 | |
| Mark without a word element (figurative) | Nov 16, 2031 | |
| HEMOLENS | Nov 16, 2031 | |
| HEMOLENS DIAGNOSTICS | Nov 16, 2031 |
Job offers
The company lists 1 job opening on its own careers page: hemolens.com/career.
Authorized Representatives
Manner of representation
Declarations of will on behalf of the company are made by at least two members of the management board acting jointly, or by a member of the management board acting jointly with a commercial proxy.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Ms Galleon Gmbh | 778 | $105,051.32 | 96.2624% |
Wojciech Tarnawski | 236 | $3,187.47 | 2.9208% |
Andrzej Kosior | 33 | $445.71 | 0.4084% |
Kryspin Mirota | 33 | $445.71 | 0.4084% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2016-01-26.
35 1050 1025 1000 0090 8086 8053
80 1050 1025 1000 0090 8060 7865
16 1050 0086 1000 0090 8691 2483
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 26,419PLN 26,419 |
Public aid
7 public aid cases recorded, with a total value of $4,088,406.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $16,968$16,968 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $16,982$16,982 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $16,652$16,652 | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-10-01 | HEMOFLOW cloud platform for non-invasive hemodynamic diagnostics | $3.4M$3,373,609 | Operational Programme Smart Growth |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| IQ Med sp. z o.o. | $301,729.42 | iq-med.pl | ||
| Radpal sp. z o.o. | $127,275.98 | radpal.pl | ||
| Medapp S.A. | $100,452.03 | medapp.pl | ||
| Idose sp. z o.o. | $68,643.58 | idose.eu | ||
| VERY Goof P.S.A. | $50,667.39 | verygoof.com | ||
| Cephio sp. z o.o. | $50,121.04 | cephio.com | ||
| Creoox R&D sp. z o.o. | $37,003.63 | creoox.com | ||
| Proton Bytes sp. z o.o. | $19,660.53 | protonbytes.com | ||
| Liver Ai sp. z o.o. | $8,443.59 | liverai.pl | ||
| Vr-Learning sp. z o.o. | $4,635.43 | vmersive.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-10-15 | Share capital increase (364,500.00 PLN → 392,400.00 PLN) | |
| 2025-08-27 | Share capital increase (327,800.00 PLN → 364,500.00 PLN) | |
| 2025-03-14 | Share capital increase (318,500.00 PLN → 327,800.00 PLN) | |
| 2024-10-22 | Share capital increase (248,750.00 PLN → 318,500.00 PLN) | |
| 2024-02-14 | Share capital increase (169,000.00 PLN → 248,750.00 PLN) |
FAQ
Last updated: 2026-07-15